SEGMENTS

12 Months Ended

Dec. 31, 2022

SEGMENTS [Abstract]

SEGMENTS

13. SEGMENTS

The Company is engaged in manufacturing, marketing and developing specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immune globulin manufacturing and development operations in Florida, acquired on June 6, 2017. The Plasma Collection Centers segment consists of ten plasma collection facilities as of December 31, 2022, nine of which were operational and collecting plasma, and seven of which hold an approved license with the FDA (and of which three facilities have received approvals from the Korean Ministry of Food and Drug Safety as well as FDA approval to implement a Hepatitis B immunization program). The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Year Ended December 31, 2022
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	144,069,543		$	9,867,315		$	142,834		$	154,079,692
Cost of product revenue		108,881,938			9,932,597			-			118,814,535
Income (loss) from operations		879,387			(17,908,378	)		(22,336,089	)		(39,365,080	)
Interest and other expense, net		(504,787	)		(3,266	)		(19,360,876	)		(19,868,929	)
Loss on extinguishment of debt		-			-			(6,669,941	)		(6,669,941	)
Net income (loss)		374,600			(17,911,644	)		(48,366,906	)		(65,903,950	)
Capital expenditures		5,246,860			8,664,311			-			13,911,171
Depreciation and amortization expense		4,708,879			2,403,572			918			7,113,369
Total assets		238,159,534			37,070,535			73,231,812			348,461,881

Year Ended December 31, 2021
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	74,935,528		$	5,864,263		$	142,834		$	80,942,625
Cost of product revenue		74,124,999			5,644,342			-			79,769,341
Loss from operations		(29,293,309	)		(12,056,364	)		(17,024,068	)		(58,373,741	)
Interest and other expense, net		(218,053	)		(5,660	)		(13,050,164	)		(13,273,877	)
Net loss		(29,511,362	)		(12,062,024	)		(30,074,232	)		(71,647,618	)
Capital expenditures		4,876,983			8,634,275			-			13,511,258
Depreciation and amortization expense		4,217,771			1,272,397			5,334			5,495,502
Total assets		208,391,019			24,681,691			43,180,014			276,252,724